[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606345":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":42,"responsibleParty":61,"collaborators":32,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":32,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":32,"enrollmentInfo":73,"targetDuration":32,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":32,"overallStatus":45,"whyStopped":32,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Group","EXPERIMENTAL","Neurosurgical patients undergoing decompressive laminectomy and\u002For spinal fusion who will receive uroselective alpha-1-adrenergic receptor antagonist Tamsulosin",[13],"Drug: Uroselective alpha-1-adrenergic receptor antagonist",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","PLACEBO_COMPARATOR","Neurosurgical patients undergoing decompressive laminectomy and\u002For spinal fusion who will receive a placebo",[19],"Other: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Uroselective alpha-1-adrenergic receptor antagonist","Subjects will receive Tamsulosin (0.4 mg daily) beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)",[9],[27],"Tamsulosin",{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Subjects will receive placebo beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)",[15],null,[34],{"name":35,"affiliation":5,"role":36},"Michelle Clarke, MD, PhD","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":32},"Neurologic Surgery Research Team","CONTACT","507-422-5673",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Mayo Clinic in Rochester","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-92.4699,44.02163,{"lat":55,"lon":54},[58,59],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":32},{"name":60,"role":36,"phone":32,"phoneExt":32,"email":32},"Michelle J Clarke, MD, PhD",{"type":36,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Michelle J. Clarke","Principal Investigator","100606345","phase-4-uroselective-alpha-1-antagonist-to-reduce-the-incidence-and-duration-of-postoperative-urinary-retention-following-spine-surgery-100606345",false,"NCT07174349","Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery","The Use of an Uroselective Alpha-1-antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery","Inclusion Criteria:\n\n* Cervical Laminectomy\n* Cervical Posterior Fusion\n* Cervical Anterior\u002FPosterior Fusion\n* Lumbar Laminectomy\n* Lumbar Posterolateral Fusion\n* Lumbar Interbody Fusion\n\nExclusion Criteria:\n\n* Cervical Anterior Discectomy and Fusion\n* Cervical Anterior Corpectomy\n* Cervical Posterior Discectomy\n* Cervical Foraminotomy\n* Lumbar Discectomy (METRx or Open)\n* Lumbar Foraminotomy\n* Lumbar Anterior Fusion\n* Myelopathy with bladder dysfunction\n* Patients currently taking an alpha-antagonist\n\n  o The following drugs are alpha antagonists: alfuzosin, doxazosin, prazosin, terazosin, tamsulosin, and phenoxybenzamine.\n* Patients with history of allergy or sensitivity to tamsulosin or other alpha-antagonist\n* History of prostatectomy or urologic surgery involving the bladder or urethra\n* Severe liver disease or end-stage renal disease\n* Patients taking strong inhibitors of CYP3A4\n\n  o The following drugs are strong inhibitors of CYP3A4: ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir\u002Fritonavir, lopinavir\u002Fritonavir, and conivaptan.\n* Mental disability or prisoner\n* Pregnancy (for anesthesia purposes)","ALL","35 Years",{"count":74,"type":75},20,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","The purpose of this research is to see if the use of tamsulosin can decrease both the incidence and duration of urinary retention, as well as hospital length of stay following spine surgery.",[81],"Urinary Retention Postoperative","2026-06-25",{"date":84,"type":85},"2026-06-29","ACTUAL",{"date":87,"type":75},"2026-10-01",{"date":89,"type":75},"2028-12-31",{"name":5,"class":6},1]